Triple-Negative Breast Cancer: Current State of the Art

Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer

(2017) A. Tutt et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial

(2017) J. O'Shaughnessy et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)

(2017) L. J. Esserman et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908

(2009) G. Frasci et al.   ANNALS OF ONCOLOGY

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

(2009) B. Corkery et al.   ANNALS OF ONCOLOGY

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

(2009) SR Young et al.   BMC CANCER

3LBA SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC)

(2009) J. Baselga et al.   EJC SUPPLEMENTS

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study

(2009) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

Significantly Longer Progression-Free Survival Withnab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

(2009) William J. Gradishar et al.   JOURNAL OF CLINICAL ONCOLOGY

Basal cell–like (triple-negative) breast cancer, a predictor of distant metastasis in African American women

(2008) Chukwuemeka U. Ihemelandu et al.   AMERICAN JOURNAL OF SURGERY

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

(2008) O. Gluz et al.   ANNALS OF ONCOLOGY

Platinum-based chemotherapy in triple-negative breast cancer

(2008) B. Sirohi et al.   ANNALS OF ONCOLOGY

Triple-Negative Breast Cancer: Risk Factors to Potential Targets

(2008) B. P. Schneider et al.   CLINICAL CANCER RESEARCH

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY